Open an account

Uniqure NV

QURE · NASDAQ

$22.72+$0.515 (+2.32%)TodayMarket closed ·
Prev close $22.20

About QURE

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company employs 221 full-time employees The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Employees
221
Headquarters
Amsterdam, Noord-Holland
Listed
Feb 5, 2014
Sector
Health Care
Industry
Biotechnology
Website
uniqure.com

QURE key statistics

Market cap
1.58B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.70M
Volume
1.42M
Open price
$22.20
High today
$22.82
Low today
$21.74
52 Week high
$71.50
52 Week low
$8.73

Uniqure NV (QURE) at a glance

Uniqure NV (QURE) last traded at $22.72, with a market cap of 1.58B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $21.74 and $22.82. The current price is 4.5% above the day's low and 0.5% below its high.

Volume so far is 1.42M shares, below the average of 3.70M shares a day.

Over the past year Uniqure NV has ranged from $8.73 to $71.50, and now sits 22% of the way up that range.

The average analyst price target is $66.58, 193.1% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

77%of 13 analyst ratings say Buy
  • Buy76.9%
  • Hold23.1%
  • Sell0.0%
Price target · 13 analystsAvg $66.58
Low
$31.31
Now
$22.72
High
$99.75

QURE news

  • Press releaseBusiness Wire

    UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop

  • Avi Kapoor

    Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday

  • Press releasePRNewswire

    uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)

  • Press releaseBusiness Wire

    QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law

  • Avi Kapoor

    Crude Oil Down 1%; US Job Openings Fall In August

  • Press releaseGlobe Newswire

    QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C.

  • Vandana Singh

    Why Is uniQure Stock Sinking on Tuesday?

  • Avi Kapoor

    Dow Tumbles 100 Points; Carnival Posts Upbeat Q3 Earnings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.